NEWS
Pirarubicin
  • Approved Drug Name
    Pirarubicin
  • CAS NO.
    72496-41-4
  • Quality Standard
    JP
  • Packaging
    10G/Bag, 20G/Bag
  • Storage Condition
    Shading,Sealing,Store at room temperature
  • Certification
    Ongoing registration

Pirarubicin(casno.72496-41-4) (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin(casno.72496-41-4) intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.
Pirarubicin(casno.72496-41-4) (THP-adriamycin or THP-doxorubicin) was found during a search of new anthracycline antibiotics among 4'-O-substituted compounds having less toxicities than other anthracycline anticancer drugs in 1979 by Umezawa et al. In its preclinical studies, this compound possessed almost similar antitumor efficacies to doxorubicin, but was effective against doxorubicin-resistant P388 and other murine tumor cell lines. This compound was rapidly incorporated into tumor cells, inhibiting DNA polymerase alpha and subsequently DNA synthesis. Inhibition of RNA synthesis was also noted. In the clinical studies, clinical responses were established against head and neck cancer, breast cancer, urogenital cancers, ovarian cancer, uterine cancer, acute leukemia, and malignant lymphoma, showing a wide antitumor spectrum clinically. Among the side effects, cardiac toxicity, alopecia and disturbance of the digestive organs were mild. From these results, THP-adriamycin seems to be a useful clinical drug for human solid tumors.
keywords
Pirarubicin Quality
Pirarubicin Manufacturers
Pirarubicin Suppliers
Pirarubicin FDA
Pirarubicin USP.EP
Pirarubicin GMP
Pirarubicin price
Pirarubicin samples
Pirarubicin(casno.72496-41-4) Shipping Condition: Pirarubicin(casno.72496-41-4) is shipped in a glass vial at ambient temperature. 
Pirarubicin(casno.72496-41-4) Storage condition: For longer shelf life, store solid powder at 4℃ desiccated, or store DMSO solution at -20℃.
Phase II clinical and pharmacological study of Pirarubicin(casno.72496-41-4) in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer:
Doxorubicin containing combination chemotherapy regimens are widely used for treatment of breast and other cancers. However, these regimens are associated with significant toxicities including myocardial dysfunction and alopecia. Analogues of doxorubicin are being developed to reduce these side effects. We conducted a Phase II trial of an anthracycline analogue, Pirarubicin(casno.72496-41-4), administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer. Patients who had received prior anthracycline therapy were excluded. The chemotherapy doses were as follows: 5-fluorouracil (500 mg/m2 on days 1 and 8), Pirarubicin(casno.72496-41-4) (50 mg/m2 on day 1), and cyclophosphamide (500 mg/m2 on day 1). Among 40 evaluable patients treated on this protocol, a major response (partial or complete remission) was observed in 26 patients (response rate, 62%; 95% confidence interval, 46-77). The median response duration was 8 months, and median survival was 16 months. Grade III/IV myelosuppression occurred in 81% of the courses. The median cumulative Pirarubicin(casno.72496-41-4) dose was 410 (range, 90-870) mg/m2. A significant decrease in left ventricular ejection fraction occurred in 12 patients (at a median cumulative Pirarubicin(casno.72496-41-4) dose of 460 mg/m2) and led to congestive heart failure in 4 of these patients (cumulative Pirarubicin(casno.72496-41-4) doses of 500, 520, 590, and 730 mg/m2, respectively). Eleven patients underwent endomyocardial biopsy, either because they experienced a drop in left ventricular ejection fraction or because they had received a cumulative Pirarubicin(casno.72496-41-4) dose of 600 mg/m2 and were still responding to the treatment. Of these, only one biopsy was found to be more than grade 1.0 (in an individual who had received a cumulative dose of 705 mg/m2). Severe alopecia occurred in two-thirds of the patients. Pharmacokinetic studies revealed a triphasic elimination of Pirarubicin(casno.72496-41-4) with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively. Total clearance of drug was 4.2 liters.1 h/kg while the cumulative 24-h urinary excretion was less than 10% of the administered dose. The activity of the combination appears to be similar to doxorubicin-containing regimens, while the incidence of alopecia appears to be lower than the historical experience with doxorubicin. However, cardiotoxicity remains a significant problem.
Pirarubicin(casno.72496-41-4) (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer:
In a phase II study, 77 patients with metastatic breast cancer were treated with Pirarubicin(casno.72496-41-4), 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracycline-containing regimens in 17. After a median of 5.5 treatment cycles (range 1–14), objective tumor response was seen in 22/71 (31%) evaluable patients (4CR, 18 PR). Stable disease occurred in 34 (48%) patients, whereas the tumor progressed in 15 (21%). Significant hematologic toxicity (WHO grade III–IV) requiring interval and/or dose adjustments was observed in 41 (58%) patients. Other treatment-related side effects were generally mild, and included alopecia in 52 (73%), nausea and/or emesis in 50 (70%), and stomatitis and diarrhea in 3 patients each. There was no treatment-related death, nor was there any evidence of cardiac toxicity thus far. In summary, the early results of this trial suggest that Pirarubicin(casno.72496-41-4) is an active and rather well tolerated drug in pretreated patients with advanced breast cancer.